Mel Mann shares his inspiring 30-year journey with chronic myeloid leukemia, from a terminal diagnosis to long-term survival.

Alana Kent took to TikTok to list the signs of the condition - which she initially believed would soon resolve - with the ...

Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel ...

Mitochondria are pivotal cellular organelles that play a crucial role in regulating metabolism and cell survival, making them ...

Precision medicine is an innovative approach that tailors treatment to the unique genetic and molecular characteristics of a ...

Updated 96-week data from the ASC4FIRST trial show asciminib significantly outperforms standard TKIs in major molecular ...

A Yale School of Medicine team has created lists of criteria to help clinicians determine when next-generation sequencing ...

Weiming Li, of Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, has presented the latest clinical data of its novel drug candidate, olverembatinib (HQP1351) ...

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Enliven Therapeutics (ELVN – Research Report) today and set a price target of ...

(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia ...

(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia ...

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...